The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|March 27, 2018
The Importance of a Pre-IND Meeting for a Successful IND
Rho offers their expertise on why it is important to have a pre-IND meeting to ensure a successful IND.
Advertisement
With recent research from Rho, a CRO, it has been presented that a pre-IND meeting is important in order to ensure a successful IND (Investigational New Drug) and a productive pre-meeting can increase that likeliness according to the
It was mentioned that a pre-IND meeting should serve its purpose to agree on a development program, initial clinical study and nonclinical program in order to bring together a meeting package which will serve as the foundation of your IND. Some topics that should be covered before filing your IND include the topic of scientific or regulatory issues such as clinical trial design, toxicity concerns, unique metabolites, novel formulation, dosing limitations, species selection, and immunogenicity.
With Rho’s input, it has been shared that the pre-IND meeting must be timed wisely, prepared, and needs to provide an early read as well as build a relationship with the FDA in order for a successful IND to take place.
To learn more about Rho, please visit
Source: Rho (2018, March 27). Rho Offers Reasons Why You Need a pre-IND Meeting [press release]
Advertisement
Related to this article
In this Q&A, Saamir Pasha and Carole Berini, PhD, of Ontada discuss what it takes to harmonize fragmented oncology data into reliable real-world evidence, how lab markers can proxy for missing functional status data, and where the biggest remaining barriers to consistent RWE generation lie.
A new white paper and public engagement process outline the FDA’s commitment to building fit-for-purpose evidentiary standards, stronger patient voice integration, and greater regulatory predictability across rare disease drug development and review.
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.
In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, describe what operationalizing regulatory-grade quality frameworks requires—and why fit-for-purpose evidence generation is a transparency and documentation discipline, not just a data cleanliness exercise.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
5